Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9816
Full metadata record
DC FieldValueLanguage
dc.contributor.authorIssa, Wen
dc.contributor.authorTochon-Danguy, Henrien
dc.contributor.authorLambert, Jen
dc.contributor.authorSachinidis, John Ien
dc.contributor.authorAckermann, Uween
dc.contributor.authorLiu, Zen
dc.contributor.authorScott, Andrew Men
dc.date.accessioned2015-05-15T23:04:08Z
dc.date.available2015-05-15T23:04:08Z
dc.date.issued2004-10-01en
dc.identifier.citationNuclear Medicine and Biology; 31(7): 839-49en
dc.identifier.govdoc15464385en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/9816en
dc.description.abstractThis study describes the synthesis, radiolabelling and biological evaluation of 5-(2,4-difluoro-5-[18F]fluoromethyl-phenyl)-2-hydroxymethyl-tetrahydrofuran-3-ol, 13. Radiolabelling was achieved by reaction of the tosylate 3 with K[18F] in the presence of Kryptofix 222. Good stability in saline and serum solutions at physiological temperatures in vitro was observed. A cell incorporation study of 13 using SW1222 tumor cells showed a linear uptake, unfortunately, in vivo studies indicated that 13 was undergoing defluorination. Rapid defluorination of the radiotracer was confirmed by an in vitro stability study in blood plasma. Finally, a comparison between the DNA uptake of 13 and tritiated thymidine was performed in vitro to asses the potential utility of more stable analogs. These studies showed that 13 and its analogs are unsuitable as potential tracers to image DNA proliferation and highlighted the difficulty in predicting the in vivo stability of novel radiotracers.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherCell Line, Tumoren
dc.subject.otherColorectal Neoplasms.metabolism.radionuclide imagingen
dc.subject.otherDNA, Neoplasm.analysis.biosynthesisen
dc.subject.otherDrug Stabilityen
dc.subject.otherFluorine Radioisotopes.diagnostic useen
dc.subject.otherHumansen
dc.subject.otherIsotope Labeling.methodsen
dc.subject.otherMetabolic Clearance Rateen
dc.subject.otherMiceen
dc.subject.otherMice, Inbred BALB Cen
dc.subject.otherOrgan Specificityen
dc.subject.otherPositron-Emission Tomography.methodsen
dc.subject.otherRadiopharmaceuticals.chemistry.diagnostic use.pharmacokineticsen
dc.subject.otherThymidine.analogs & derivatives.diagnostic use.pharmacokineticsen
dc.subject.otherTissue Distributionen
dc.titleSynthesis and evaluation of a thymidine analog for positron emission tomography study of tumor DNA proliferation in vivo.en
dc.typeJournal Articleen
dc.identifier.journaltitleNuclear medicine and biologyen
dc.identifier.affiliationCentre for PET, Austin Health Studley Rd, Melbourne 3084, VIC Australiaen
dc.identifier.doi10.1016/j.nucmedbio.2004.03.013en
dc.description.pages839-49en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/15464385en
dc.type.austinJournal Articleen
local.name.researcherAckermann, Uwe
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.languageiso639-1en-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

34
checked on Dec 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.